Document is current
Any future updates will be listed below
-
Authors
Morsink, Chiron https://orcid.org/0000-0001-5467-6979
Klaassen, Nienke
van de Maat, Gerrit
Boswinkel, Milou
Arranja, Alexandra
Bruggink, Robin
van Houwelingen, Ilva
Schaafsma, Irene
Hesselink, Jan Willem
Nijsen, Frank
van Nimwegen, Bas
-
Funding
Funding for this research was provided by:
Stichting voor de Technische Wetenschappen (15499)
- License Information
-
More Information
Article History
Received: 10 July 2024
Accepted: 5 September 2024
First Online: 14 October 2024
Declarations
:
: The clinical study was reviewed and approved by the Ethical Committee of the Academic Veterinary Hospital of Utrecht University and the Animal Welfare Body Utrecht (Protocol number 10813-2021-01, approval date 12-09-2021). Informed consent was obtained from the owners for the participation of their animals in this study.
: Not applicable.
: JFWN is a co-founder of Quirem Medical which was acquired by Terumo Europe NV in July 2020. JFWN has a scientific advisory role and is entitled to certain milestone payments from Terumo that are related to Quirem’s financial, operational, and regulatory performance in the future. Furthermore, JFWN is an inventor of the patents related to radioactive microspheres that are assigned to University Medical Center Utrecht Holding BV, Quirem Medical, or BASF Corp. The activities of JFWN within Quirem Medical are approved and supported by the Board of Directors of the Radboudumc. GHvdM, AGA, and IvH (until November 2023) are employees of Quirem Medical B.V. All other authors declare that they have no competing interests.
